Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation (NCT05758909) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation
Spain585 participantsStarted 2023-04-04
Plain-language summary
Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patients who meet all of the following conditions will be included:
* Patients ≥ 18 years undergoing transfemoral TAVI implantation scheduled, performed on an outpatient basis.
* Patients with percutaneous implant.
* Patients undergoing the procedure under superficial sedation or Local anesthesia.
* Patients with baseline narrow QRS that does not change after implantation, or definitive pacemaker carrier.
* Patients who have signed the informed consent.
Exclusion Criteria:
Patients who do not meet any of the following conditions:
* Patients with a wide QRS (greater than or equal to 120 msec) at baseline, with the except for patients with permanent pacemakers.
* Hospitalized patients undergoing urgent TAVI implantation.
* Patients with access other than percutaneous transfemoral.